Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.

Hiroshi YasuiMasayuki KobayashiKota SatoKanya KondohTadao IshidaYuta KaitoHideto TamuraHiroshi HandaYutaka TsukuneMakoto SasakiNorio KomatsuNorina TanakaJunji TanakaMasahiro KizakiToyotaka KawamataJunya MakiyamaKazuaki YokoyamaSeiya ImotoArinobu TojoYoichi Imai

Published in: International journal of clinical oncology (2021)

These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peripheral blood
multiple myeloma
prognostic factors
peritoneal dialysis
patient reported outcomes
climate change